The World Health Organization now r...

The World Health Organization now recognizes migraine as individual of the most disabling medical conditions. In the United States, annual direct medical take away froms of more than $1 billion portray by action only a fraction of the total charge of migraine, which is estimated to charge employers more than $13 billion each year. The 28 million Americans who have unadorned migraines report an average of common to five attacks per month of moderate to relentless pain, usually unilateral and accompanied at other symptoms, such as gastrointestinal invert photophobia, and phonophobia. The severity of attacks and the related symptoms vary widely among patients. The importance of individualizing therapy to the specific penurys of each patient is emphasized in a latter review by Silberstein.

Accurately diagnosing the condition, educating patients, and identifying comorbidities are essential stairs in the management of migraine. Headache diaries can validate the pattern of attacks and help the physician bring to maturity treatment goals. Headache severity and disability scales, so as the Migraine Disability Assessment Scale (MIDAS) or the Headache Impact trial can be used to quantify headache morbidity and stratify patients for treatment.

Screening patients with migraine for conditions of increased prevalence (eg Raynaud's disease, depression, mitral valve prolapse, anxiety disorders) facilitates patient care and helps the physician chosen antimigraine treatment with specific characteristics to ameliorate comorbid conditions. Specific treatment of migraine is available to manage acute attacks and model the frequency and severity of attacks. Many patients benefit from a combination of acute and prophylactic therapy.

Acute treatments generally are classified as nonspecific (symptomatic) or migraine-specific. The choice of treatment strategy and individual agent hangs on many factors, including headache severity and frequency; characteristics of the attack; patient characteristics and comorbidities; and put drugs into characteristics, including efficacy, side drifts route of administration, and potential for overuse. Acute treatments should not be used more than couple to three days per week because of their potential for adverse events such as rebound headache.

Nonspecific treatments include analgesics and antiemetics to combat the in the greatest degree troublesome symptoms for patients with mild to moderate migraine. Evidence supports the use of aspirin and several nonsteroidal anti-inflammatory medicines with or with-out caffeine, to relieve symptoms of acute migraine. Nonoral administration may be useful because of vomiting and delayed gastric absorption during migraine attacks. Antiemetics in the same state [i]or[/i] condition as prochlorperazine can control vomiting and relieve migraine. Although opioids are effective, they usually are reserv for liberation medication or for the treatment of pregnant women with migraine. Use of barbiturate medications is not supported by means of the evidence and is associated with a significant risk of overuse and withdrawal problems

The specific antimigraine remedys ergots and triptans, are strong 5-HT1B/1D agonists and are indicated for the treatment of moderate to stern migraine episodes. Both classes of unsalable articles are effective, but ergots have more side results and are contraindicated in a range of conditions. Ergotamine and dihydroergotamine can be administered through various routes. Intravenous dihydroergotamine is used often for intractable migraine.

The triptans are more selective receptor agonists than the spurred ryes and, thus, have fewer adverse general intents The currently available triptans vary in spe of storming rate of headache recurrence, and efficacy. Clinical trials generally report "any response" or "complete pain-free" status sum of two units hours after the medication is used. Because the placebo weight can be marked in patients with migraine, arises are most meaningful when the placebo replication is deducted (i.e., therapeutic gain).

Triptans are greatest in number effective if taken early during the migraine attack. These unsalable articles generally are safe except in patients with cardiovascular risk factors, on the contrary some triptans interact with monoamine oxidase inhibitors and other mix with drugss including propranolol. Nonoral preparations provide the fastest attack of action and may be necessary in patients with vomiting.

Of the oral triptans, almotriptan, eletriptan, and rizatriptan have the greatest efficacy and fastest first brunt of action. Although the choice of agent for each patient hangs on efficacy, speed of attack chance of recurrent symptoms, and side imports patients show significant idiosyncratic answer and may need to put to proof several different types and impregnabilitys of triptans before finding individual that best alleviates their symptoms.

Prophylactic treatments aim to abate the frequency, severity, and duration of migraine attacks. They should be considered when migraine substantially interferes with the patient's life and in special circumstances, in the same state [i]or[/i] condition as when there are contraindications to or simple reactions from acute treatment. Several classes of prophylactic put drugs intos are available. The choice of agent hangs on efficacy, potential for adverse meanings and impact on comorbidities. In general, prophylactic therapy should begin at a depressed dose and increase slowly until therapeutic import or side effects are significant. An appropriate trial of prophylaxis requires several month at the cloyed therapeutic dosage. Patients often benefit from a combination of medication and non-pharmacologic interventions (eg relaxation training, cognitive behavioral therapy, bio-feedback) in migraine prophylaxis.